Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

ual sales of approximately $800 million in the US alone."

About Gentamicin Surgical Implant

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It was developed using Innocoll's proprietary collagen-based technology, CollaRx(R), and is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) at the target tissue while maintaining low systemic levels well below the toxicity threshold. The product is indicated as an adjunct to systemic antibiotic therapy for the prevention of surgical site infections and for the treatment of deep, localized infections in both hard and soft tissues. There are more than 60 prospective clinical trials and published case reports totalling over 7,500 patients documenting safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and is marketed by EUSA Pharma under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R) and CRONOCOL(R).

GENTAMICIN SURGICAL IMPLANT is under development in the US for the prevention of surgical site infections. An IND has been approved by the FDA and Innocoll plans to conduct two US multi-centered phase 3 clinical trials; one in cardiac surgery patients at higher risk of surgical site infection and the other in patients undergoing open colorectal surgery. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Co-ordinating Center for both trials. Independent market research recently performed by L.E.K. Consulting projected peak US sales of greater than US$200 million per annum.

About CollaRx(R) Ge
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... Sept. 30, 2014  Decision Resources Group finds that the ... , China , India ... a strong rate through 2023. Dental implant procedure volumes will grow ... awareness rises. Other key findings from Decision Resources Group,s ... market: , Dental implant penetration: Penetration of dental ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... BALTIMORE, April 24, 2012   The University of Maryland ... Vice President of Research and Development at MedImmune ... the UM Health Sciences Research Park Corporation (RPC) ... ) "The BioPark leadership team is ...
... Simcere Pharmaceutical Group (NYSE: SCR ), a ... marketing of branded generic and proprietary pharmaceuticals in China, ... results for the first quarter ended March 31, 2012 ... in the United States. Simcere,s management will host an ...
Cached Medicine Technology:University of Maryland BioPark Announces MedImmune's Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park 2University of Maryland BioPark Announces MedImmune's Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park 3Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012 2
(Date:10/1/2014)... of scientists has shown that more than 80 per ... drugs. , The study found that medicines called ,JAK ... genetic mutation that is present in more than 80 ... currently used, or are in clinical trials, for diseases ... , Bowel cancer is the second-most common cancer in ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining ... , Senior citizens can purchase a joint life insurance ... A joint policy is cheaper, but will only pay ... Life insurance can be used to cover important funeral ... online, as the application process is simple and straightforward. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... 2014 Join the more than 80 golfers ... Center’s first ever charity golf tournament to benefit Project HEAL, ... disorders who cannot afford treatment. The tournament will be held ... Mo. , The day-long event starts with 10:30 a.m. ... award dinner will begin at 5 p.m. and will include ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... new drugs is a highly costly and time-consuming process. Of ... or have unwanted side effects. Now a research team led ... tiny molecular "binder" that has the potential to change this ... journal Angewandte Chemie , presents the concept of a ...
... general wards are twice as likely to die as those ... treatment of the condition, published online in the journal ... comes to appropriate investigations and treatment, the findings suggest, although ... accounted for more than a quarter of a million hospital ...
... and patient embarrassment may prevent dermatologists, internists and ... to a report in the January issue of ... JAMA/Archives journals. However, dermatologists are significantly more likely ... screenings. Skin cancer is the most frequently ...
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at ... can detect the deadly skin cancer at an early stage, ... prevents some people from having a doctor examine their skin ... Archives of Dermatology . People at high risk ...
... First Nations (North American Indian) babies are linked to a ... 4 weeks to 1 year of age), according to a ... Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100837.pdf . High ... being born above the 90th percentile relative to a fetal ...
... News) -- Cigarettes start to destroy a smoker,s DNA ... the habit causes immediate genetic damage and quickly raises ... here should serve as a stark warning to those ... author Stephen S. Hecht, from the Masonic Cancer Center ...
Cached Medicine News:Health News:Breakthrough for more efficient drug development 2Health News:Heart failure patients twice as likely to die if admitted to general wards 2Health News:Clinicians cite time, patient embarrassment as barriers to performing skin cancer exams 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:High birth weight in First Nations babies linked to a higher risk of postneonatal death 2Health News:Smoking Damages DNA Within Minutes, Research Shows 2
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: